企業プロフィール
IGC Pharma, Inc. 株価・ニュース・カタリスト
- ティッカー:
- IGC
- 取引所:
- NYSE
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
0.27 USD (+0.41%)
終値
最終更新: 2026年10月1日
29M USD
時価総額
株価変動の要因
2026年10月1日 時点で IGC は 0.41% 上昇し、$0.2700 で取引を終えました。現在のニュース監視期間内に同社の新しいニュースは確認されませんでした。
企業概要
Alzheimer's Disease Drug Developer
IGC Pharma develops therapies and digital tools for Alzheimer's disease and related neuropsychiatric symptoms. Its portfolio includes a clinical-stage treatment for agitation and earlier disease-modifying research.
IGC-AD1 for Agitation
IGC-AD1 is an oral formulation being evaluated for agitation in patients with Alzheimer's disease. The Phase 2 CALMA program is intended to assess whether the candidate can reduce behavioral symptoms while maintaining an acceptable safety profile.
TGR-63 Disease-Modifying Research
TGR-63 is a preclinical small molecule being studied for its ability to interfere with amyloid-related processes and protect neurons. The program represents the company's longer-term effort to address underlying disease biology.
Cannabinoid and Small-Molecule Expertise
IGC's research incorporates cannabinoid pharmacology and other small-molecule approaches. The company uses formulation, preclinical, and clinical-development capabilities to advance candidates for central nervous system disorders.
AI and Biomarker Platforms
The MINT-AD and AHA initiatives apply artificial intelligence to Alzheimer's diagnosis, clinical-trial analysis, and drug development. These tools are intended to complement the therapeutic pipeline with digital and biomarker capabilities.
今後のカタリスト
最近のニュース
ニュースタイトルは機械翻訳です。詳細は英語の原文をご覧ください。
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。